根据提交给美国证券交易委员会（SEC）的最新文件，Orthofix Medical Inc. 公布了其2026财年的财务展望。公司预计，全年净销售额将达到8.38亿美元至8.48亿美元区间。同时，在非美国通用会计准则（Non-GAAP）下，经调整的息税折旧摊销前利润（Adjusted EBITDA）预计在9000万美元至9300万美元之间。
这份业绩指引为市场提供了衡量该公司未来增长与盈利能力的清晰标尺。销售额预期反映了公司对其核心业务持续发展的信心，而调整后EBITDA目标则凸显了管理层在提升运营效率和盈利能力方面的专注。投资者将密切关注Orthofix Medical能否在未来财年实现这些既定目标，以评估其长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.